B+
Bull case
25%
Probability
Target price
$25.00
+43.8% vs current
QDEL
QuidelOrthoANasdaq / Health Care Equipment & Services
Last Price
At close
2026-07-18
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$20.50
+18.0% vs current
B-
Bear case
25%
Probability
Target price
$13.50
-22.3% vs current
AI sentiment snapshot
Latest data as of 2026-07-18
Recent news sentiment (30D)
+30.0
Positive
Company
-
Unavailable
Macro
+30.0
Positive
Pulse
-
Unavailable
Sentiment proxy
+60.0
Score
AI commentary
The primary-source record supports a cautious positive recovery thesis, not a confirmed turnaround. Stored earnings context notes shares were up 24.1% after the prior earnings report, while late-June coverage included a sale-talk headline; neither establishes durable operating improvement. Social coverage and verified post-print analyst revisions are unavailable, limiting confidence.
RankAlpha Sentiment Codex - 2026-07-18
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-10-16eventChina IVD pricing-rule clarificationHigh impact
Final China NHSA IVD pricing guidelines and implementation timing could remove or increase a major source of uncertainty in Labs demand. Management said the updated guidance incorporates the current draft but that the impact cannot be fully assessed until final rules and timelines are known [#SEC-8K-2026-05-05].
2026-10-16catalystProof of stabilization against reduced 2026 guidanceHigh impact
The key near-term test is whether Labs and Point of Care trends stabilize enough to support the reset outlook. Q1 revenue was $620 million, with Point of Care down 34% and Labs down 5%; management reduced full-year revenue, adjusted EBITDA, EPS, and free-cash-flow guidance [#SEC-8K-2026-05-05].
2027-07-18catalystLEX platform and product launches support recoveryHigh impact
QuidelOrtho completed the LEX Diagnostics acquisition and cited the U.S. High-Sensitivity Troponin launch and VITROS 450 rollout in select international markets as longer-term growth drivers. Adoption and mix improvement remain unproven [#SEC-8K-2026-05-05].
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology